Testing a new medication for kidney protein loss diseases

Plain-English translation of NCT07614477 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing a new medication called to see if it can help people with three types of kidney diseases: minimal change disease, IgA nephropathy, or focal segmental glomerulosclerosis. All three conditions cause your kidneys to leak protein into your urine, which can damage your kidneys over time. The medication works by calming your immune system in a new way, without directly affecting certain immune cells.

People with these kidney diseases often don't have enough treatment options, especially if they don't respond well to current medications or can't tolerate them. This trial exists to see if this new approach to calming the immune system might offer a better or additional option for patients who need help.

Do you qualify?

You likely qualify if…

you have been diagnosed with minimal change disease, IgA nephropathy, or focal segmental glomerulosclerosis confirmed by a kidney biopsy
your kidney function (measured by eGFR) is at least 45 mL/min/1.73 m²
you are between 18 and 75 years old
for FSGS or MCD: you are losing significant protein in your urine (more than 3.5 g per day) and have low blood protein levels
for IgAN: you are losing protein in your urine (at least 0.8 g per day) and have been stable on certain blood pressure medications for at least 12 weeks

You likely don't qualify if…

you have a secondary or inherited form of these kidney diseases, or a specific severe form called collapsing FSGS
you have diabetes or a history of diabetes
you have an active infection that requires treatment, including HIV, hepatitis B or C, TB, or syphilis
you have a high risk of bleeding
you have a body mass index (BMI) of 35 or higher and have FSGS or MCD

What participation looks like

You would take the medication by mouth twice a day (four capsules total daily) for 52 weeks. You will have regular visits at one of about 30 study centers in China, where doctors will check your kidney function, measure protein in your urine, do blood tests, and monitor how you're feeling and any side effects. The study will track how well the treatment works and whether it is safe for you.

AI-generated summary from trial data · Aug 27, 2026 · Not medical advice

Trial locations(2 sites)

China

Peking University First Hospital, Beijing, Beijing Municipality

Tianjin Medical University General Hospital, Tianjin, Hebei